Recurrent Breast Cancer Completed Phase 1 Trials for Lapatinib (DB01259)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01245205Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerTreatment